Synthesis, Characterization, DFT Study, and In Silico Evaluation of a Thiophene-Thiazole Scaffolds as a Potential Mycobacterium tuberculosis CYP51 Inhibitor †
Abstract
1. Introduction
2. Experimental
2.1. Materials and Method
2.2. General Methodology for the Synthesis of (E)-4-(2-(2-(1-(5-Chlorothiophen-2-yl)ethylidene)hydrazinyl)thiazol-4-yl)benzonitrile (CTHTBN)
2.3. Physical and Spectral Data for Synthesized Compound
2.4. Computational Details
2.5. Molecular Docking Studies
3. Results and Discussion
3.1. Chemistry
3.2. Computational Study
3.2.1. Molecular Structures
3.2.2. Frontier Molecular Orbitals’ and Global Descriptors’ Study
3.2.3. Molecular Electrostatic Potential Surface Analysis
3.3. Molecular Docking Study
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Chakaya, J.; Khan, M.; Ntoumi, F.; Aklillu, E.; Fatima, R.; Mwaba, P.; Kapata, N.; Mfinanga, S.; Hasnain, S.E.; Katoto, P.D.; et al. Global Tuberculosis Report 2020–Reflections on the Global TB burden, treatment and prevention efforts. Int. J. Infect. Dis. 2021, 113, S7–S12. [Google Scholar] [CrossRef]
- Sankineni, S.; Chauhan, S.; Shegokar, R.; Pathak, Y. Global health and tuberculosis; past, present, and future. In Tubercular Drug Delivery Systems: Advances in Treatment of Infectious Diseases; Springer International Publishing: Cham, Switherland, 2023; pp. 1–13. [Google Scholar]
- Bu, Q.; Qiang, R.; Fang, L.; Peng, X.; Zhang, H.; Cheng, H. Global trends in the incidence rates of MDR and XDR tuberculosis: Findings from the global burden of disease study 2019. Front. Pharmacol. 2023, 14, 1156249. [Google Scholar] [CrossRef] [PubMed]
- Cui, K.; Zhao, X.; Liu, W.; Bai, L. Global, regional, and national burden and trends of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis in adolescents and adults aged 15–49 years from 2010 to 2021: Insights from the global burden of disease study 2021. BMC Med. 2025, 23, 445. [Google Scholar] [CrossRef] [PubMed]
- Khawbung, J.L.; Nath, D.; Chakraborty, S. Drug resistant Tuberculosis: A review. Comp. Immunol. Microbiol. Infect. Dis. 2021, 74, 101574. [Google Scholar] [CrossRef] [PubMed]
- Baranwal, J.; Kushwaha, S.; Singh, S.; Jyoti, A. A review on the synthesis and pharmacological activity of heterocyclic compounds. Curr. Phys. Chem. 2023, 13, 2–19. [Google Scholar] [CrossRef]
- Kabir, E.; Uzzaman, M. A review on biological and medicinal impact of heterocyclic compounds. Results Chem. 2022, 4, 100606. [Google Scholar] [CrossRef]
- Qadir, T.; Amin, A.; Sharma, P.K.; Jeelani, I.; Abe, H. A review on medicinally important heterocyclic compounds. Open Med. Chem. J. 2022, 16, e2202280. [Google Scholar] [CrossRef]
- Luo, W.; Liu, Y.; Qin, H.; Zhao, Z.; Wang, S.; He, W.; Tang, S.; Peng, J. Nitrogen-containing heterocyclic drug products approved by the FDA in 2023: Synthesis and biological activity. Eur. J. Med. Chem. 2024, 279, 116838. [Google Scholar] [CrossRef]
- Gharge, S.; Alegaon, S.G. Recent studies of nitrogen and sulfur containing heterocyclic analogues as novel antidiabetic agents: A review. Chem. Biodivers. 2024, 21, e202301738. [Google Scholar] [CrossRef] [PubMed]
- Zheng, Y.; Li, J.; Wu, W.; Qi, C.; Jiang, H. Oxygen-, nitrogen-, and sulfur-containing heterocycles: Recent advances in De Novo synthesis and prospect. Org. Process Res. Dev. 2024, 28, 2988–3025. [Google Scholar] [CrossRef]
- Pennington, L.D.; Collier, P.N.; Comer, E. Harnessing the necessary nitrogen atom in chemical biology and drug discovery. Med. Chem. Res. 2023, 32, 1278–1293. [Google Scholar] [CrossRef]
- Chugh, V.; Pandey, G.; Rautela, R.; Mohan, C. Heterocyclic compounds containing thiazole ring as important material in medicinal chemistry. Mater. Today Proc. 2022, 69, 478–481. [Google Scholar] [CrossRef]
- Dawood, D.H.; Anwar, M.M. Recent advances in the therapeutic insights of thiazole scaffolds as acetylcholinesterase inhibitors. Eur. J. Med. Chem. 2025, 287, 117331. [Google Scholar] [CrossRef]
- Petrou, A.; Fesatidou, M.; Geronikaki, A. Thiazole ring—A biologically active scaffold. Molecules 2021, 26, 3166. [Google Scholar] [CrossRef] [PubMed]
- Kassem, A.F.; Althomali, R.H.; Anwar, M.M.; El-Sofany, W.I. Thiazole moiety: A promising scaffold for anticancer drug discovery. J. Mol. Struct. 2024, 1303, 137510. [Google Scholar] [CrossRef]
- Khamitova, Ц.1.K.; Berillo, D.; Lozynskyi, A.; Konechnyi, Y.; Mural, D.; Georgiyants, V.; Lesyk, R. Thiadiazole and thiazole derivatives as potential antimicrobial agents. Mini Rev. Med. Chem. 2024, 24, 531–545. [Google Scholar] [CrossRef]
- Sharma, D.; Sharma, V.; Sharma, A.; Goyal, R.; Tonk, R.K.; Thakur, V.K.; Sharma, P.C. Green chemistry approaches for thiazole containing compounds as a potential scaffold for cancer therapy. Sustain. Chem. Pharm. 2021, 23, 100496. [Google Scholar] [CrossRef]
- Hosseininezhad, S.; Ramazani, A. Thiazole ring-the antimicrobial, anti-inflammatory, and anticancer active scaffold. Arab. J. Chem. 2023, 16, 105234. [Google Scholar] [CrossRef]
- Bhanwala, N.; Gupta, V.; Chandrakar, L.; Khatik, G.L. Thiazole heterocycle: An incredible and potential scaffold in drug discovery and development of antitubercular agents. ChemistrySelect 2023, 8, e202302803. [Google Scholar] [CrossRef]
- Kumar, A.; Debnath, U.; Roy, K.K. Thiazole-Scaffold-Based Anti-tubercular Agents: A Review on Synthesis and Structural Modifications. Synlett 2025, 36, 2705–2731. [Google Scholar]
- Archna; Pathania, S.; Chawla, P.A. Thiophene-based derivatives as anticancer agents: An overview on decade’s work. Bioorganic Chem. 2020, 101, 104026. [Google Scholar] [CrossRef]
- Mabkhot, Y.N.; Kaal, N.A.; Alterary, S.; Mubarak, M.S.; Alsayari, A.; Bin Muhsinah, A. New thiophene derivatives as antimicrobial agents. J. Heterocycl. Chem. 2019, 56, 2845–2953. [Google Scholar] [CrossRef]
- Mishra, I.; Sharma, V.; Kumar, N.; Krishna, G.; Sethi, V.A.; Mittal, R.; Dhakad, P.K.; Mishra, R. Exploring Thiophene Derivatives: Synthesis Strategies and Biological Significance. Med. Chem. 2025, 21, 11–31. [Google Scholar] [CrossRef]
- Cavasotto, C.N.; Aucar, M.G.; Adler, N.S. Computational chemistry in drug lead discovery and design. Int. J. Quantum Chem. 2019, 119, e25678. [Google Scholar] [CrossRef]
- Cai, J.H.; Zhu, X.Z.; Guo, P.Y.; Rose, P.; Liu, X.T.; Liu, X.; Zhu, Y.Z. Recent updates in click and computational chemistry for drug discovery and development. Front. Chem. 2023, 11, 1114970. [Google Scholar] [CrossRef] [PubMed]
- Sadybekov, A.V.; Katritch, V. Computational approaches streamlining drug discovery. Nature 2023, 616, 673–685. [Google Scholar] [CrossRef] [PubMed]
- Hasnain, M.; Urrehman, S.; Yousuf, A.; Ali, M.A.; Fatima, T.; Bibi, S.; Bai, F.Q. DFT investigation of functional group effects on the structure of tetraphenyl porphyrin for enhanced nonlinear optical properties. Chem. Papers 2025, 79, 6809–6824. [Google Scholar] [CrossRef]
- Guan, H.; Sun, H.; Zhao, X. Application of density functional theory to molecular engineering of pharmaceutical formulations. Int. J. Mol. Sci. 2025, 26, 3262. [Google Scholar] [CrossRef]
- Saini, M.; Mehra, N.; Kumar, G.; Paul, R.; Kovács, B. Molecular and structure-based drug design: From theory to practice. In Advances in Pharmacology; Academic Press: Cambridge, MA, USA, 2025; Volume 103, pp. 121–138. [Google Scholar]
- Rajasekhar, S.; Karuppasamy, R.; Chanda, K. Exploration of potential inhibitors for tuberculosis via structure-based drug design, molecular docking, and molecular dynamics simulation studies. J. Comput. Chem. 2021, 42, 1736–1749. [Google Scholar] [CrossRef]
- Fischer, A.; Smiesko, M.; Sellner, M.; Lill, M.A. Decision making in structure-based drug discovery: Visual inspection of docking results. J. Med. Chem. 2021, 64, 2489–2500. [Google Scholar] [CrossRef] [PubMed]
- Frisch, M.J.T.; Schlegelhb, S.; Robbma, C.J.; Montgomery, J.A., Jr.; Vreven, T.; Kudin, K.N.; Burant, J.C.; Millam, J.M.; Iyengar, S.S.; Tomasi, J.; et al. Gaussian 03, Revision C.02; ScienceOpen, Inc.: Lexington, MA, USA, 2004. [Google Scholar]
- Trott, O.; Olson, A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010, 31, 455–461. [Google Scholar] [CrossRef] [PubMed]
- Alhawarri, M.B. Exploring the Anticancer Potential of Furanpydone A: A Computational Study on its Inhibition of MTHFD2 Across Diverse Cancer Cell Lines. Cell Biochem. Biophys. 2025, 83, 437–454. [Google Scholar] [CrossRef] [PubMed]
- Pitaloka, D.A.E.; Ramadhan, D.S.F.; Arfan; Chaidir, L.; Fakih, T.M. Docking-based virtual screening and molecular dynamics simulations of quercetin analogs as enoyl-acyl carrier protein reductase (InhA) inhibitors of Mycobacterium tuberculosis. Sci. Pharm. 2021, 89, 20. [Google Scholar] [CrossRef]









| Bond | Length (Å) | Bond | Length (Å) |
|---|---|---|---|
| C1–C2 | 1.4293 | C12–C13 | 1.3668 |
| C1–N8 | 1.1557 | C13–H28 | 1.0771 |
| C2–C3 | 1.4016 | N14–N15 | 1.3524 |
| C2–C7 | 1.4036 | N14–H29 | 1.0123 |
| C3–C4 | 1.3867 | N15–C16 | 1.2913 |
| C3–H24 | 1.083 | C16–C17 | 1.511 |
| C4–C5 | 1.4032 | C16–C18 | 1.463 |
| C4–H25 | 1.0816 | C17–H30 | 1.0884 |
| C5–C6 | 1.404 | C17–H31 | 1.096 |
| C5–C12 | 1.4729 | C17–H32 | 1.0963 |
| C6–C7 | 1.3848 | C18–C19 | 1.3752 |
| C6–H26 | 1.0832 | C18–S22 | 1.7568 |
| C7–H27 | 1.0829 | C19–C20 | 1.4172 |
| S9–C10 | 1.7746 | C19–H33 | 1.0807 |
| S9–C13 | 1.7401 | C20–C21 | 1.3654 |
| C10–N11 | 1.2908 | C20–H34 | 1.0809 |
| C10–N14 | 1.3743 | C21–S22 | 1.7366 |
| N11–C12 | 1.3847 | C21–Cl23 | 1.7308 |
| Angle | Value (°) | Angle | Value (°) |
|---|---|---|---|
| C2−C1−C3 | 120.4269 | C2−C1−C7 | 120.2134 |
| C3−C2−C7 | 119.3598 | C2−C3−C4 | 120.1659 |
| C2−C3−C24 | 119.5589 | C4−C3−C24 | 120.2752 |
| C3−C4−C5 | 120.913 | C3−C4−C25 | 120.615 |
| C5−C4−C25 | 118.472 | C4−C5−C6 | 118.4601 |
| C4−C5−C12 | 119.5111 | C6−C5−C12 | 122.0287 |
| C5−C6−C7 | 121.0183 | C5−C6−C26 | 120.2801 |
| C7−C6−C26 | 118.7014 | C2−C7−C6 | 120.0828 |
| C2−C7−C27 | 119.5739 | C6−C7−C27 | 120.3433 |
| C10−C9−C13 | 87.7914 | C9−C10−C11 | 114.9838 |
| C9−C10−C14 | 118.5983 | C11−C10−C14 | 126.4179 |
| C10−C11−C12 | 111.3402 | C5−C12−C11 | 118.5242 |
| C5−C12−C13 | 126.2554 | C11−C12−C13 | 115.2198 |
| C9−C13−C12 | 110.6647 | C9−C13−C28 | 119.6355 |
| C12−C13−C28 | 129.6988 | C10−C14−C15 | 120.74 |
| C10−C14−C29 | 118.0429 | C15−C14−C29 | 121.2143 |
| C14−C15−C16 | 118.4518 | C15−C16−C17 | 123.5084 |
| C15−C16−C18 | 115.6809 | C17−C16−C18 | 120.8103 |
| C16−C17−C30 | 112.4121 | C16−C17−C31 | 110.9692 |
| C16−C17−C32 | 110.9688 | C30−C17−C31 | 107.1802 |
| C30−C17−C32 | 107.0927 | C31−C17−C32 | 107.9974 |
| C16−C18−C19 | 127.7652 | C16−C18−C22 | 121.8274 |
| C19−C18−C22 | 110.407 | C18−C19−C20 | 113.9804 |
| C18−C19−C33 | 121.6433 | C20−C19−C33 | 124.3763 |
| C19−C20−C21 | 112.139 | C19−C20−C34 | 124.6921 |
| C21−C20−C34 | 123.1689 | C20−C21−C22 | 112.5195 |
| C20−C21−C23 | 127.208 | C22−C21−C23 | 120.2724 |
| C18−C22−C21 | 90.9541 | - | - |
| Parameter | Value |
|---|---|
| E (a.u.) | −2092.12 |
| EHOMO (eV) | −5.75 |
| ELUMO (eV) | −2.03 |
| I (eV) | 5.75 |
| A (eV) | 2.03 |
| Eg (eV) | 3.72 |
| Dipole moment (Debye) | 7.9381 |
| Parameter | Value |
|---|---|
| Chemical Hardness ɳ (eV) | 1.86 |
| Chemical Softness σ (eV−1) | 0.5376 |
| Electronegativity χ (eV) | 3.89 |
| Chemical Potential µ (eV) | −3.89 |
| Global Electrophilicity ω (eV) | 4.07 |
| Maximum Electronic Charge ΔNmax | 2.09 |
| PDB ID | Docking Score (kcal/mol) | Key Interactions |
|---|---|---|
| 1E9X (M. tuberculosis CYP51) | −8.8 | π–Sulfur interactions (MET79, Phe83); π–π stacking (TYR76); π–π T-shaped interactions (PHE83, Heme group); π–Alkyl interactions (LEU321, ALA256, Heme alkyl group) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Shinde, R.A.; Adole, V.A.; Jagdale, B.S. Synthesis, Characterization, DFT Study, and In Silico Evaluation of a Thiophene-Thiazole Scaffolds as a Potential Mycobacterium tuberculosis CYP51 Inhibitor. Chem. Proc. 2025, 18, 58. https://doi.org/10.3390/ecsoc-29-26901
Shinde RA, Adole VA, Jagdale BS. Synthesis, Characterization, DFT Study, and In Silico Evaluation of a Thiophene-Thiazole Scaffolds as a Potential Mycobacterium tuberculosis CYP51 Inhibitor. Chemistry Proceedings. 2025; 18(1):58. https://doi.org/10.3390/ecsoc-29-26901
Chicago/Turabian StyleShinde, Rahul A., Vishnu A. Adole, and Bapu S. Jagdale. 2025. "Synthesis, Characterization, DFT Study, and In Silico Evaluation of a Thiophene-Thiazole Scaffolds as a Potential Mycobacterium tuberculosis CYP51 Inhibitor" Chemistry Proceedings 18, no. 1: 58. https://doi.org/10.3390/ecsoc-29-26901
APA StyleShinde, R. A., Adole, V. A., & Jagdale, B. S. (2025). Synthesis, Characterization, DFT Study, and In Silico Evaluation of a Thiophene-Thiazole Scaffolds as a Potential Mycobacterium tuberculosis CYP51 Inhibitor. Chemistry Proceedings, 18(1), 58. https://doi.org/10.3390/ecsoc-29-26901

